Investing
Cathie Wood's ARK Invest Sells Over 60,000 Shares of Pluristem Therapeutics
Published:
One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 62,000 shares of Pluristem Therapeutics Inc. (NASDAQ: PSTI) on Tuesday, as the share price of this fund traded up less than 1% in the day’s session. That share price has greatly improved over the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 62,738 shares of Pluristem. At Tuesday’s closing price, this would have valued this sale at roughly $252,000. This is only a small fraction of the total holdings. This fund is up 84% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
Fund | Ticker | Company | Shares |
---|---|---|---|
ARKG | CSTL | Castle Biosciences | 4,800 |
ARKG | PSTI | Pluristem Therapeutics | 62,738 |
ARKQ | GLEO | Galileo Acquisition | 1,798 |
ARKQ | RAVN | Raven Industries | 8,104 |
ARKW | LC | LendingClub | 82 |
ARKW | PD | PagerDuty | 6,567 |
ARKW | ROKU | Roku | 5,986 |
ARKW | SE | Sea | 21,337 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.